Day: March 17, 2022

Ayr Wellness Reports Fourth Quarter and Full Year 2021 Results

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

Q4 2021 Revenue of $111.8 Million, up 16% sequentially Q4 2021 Adjusted EBITDA of $26.1 Million, flat sequentially FY 2021 Revenue and Adjusted EBITDA of $357.6 Million and $98.0 Million, up 131% and 84% Year-over-Year, respectively US GAAP Operating Loss of $13.8 Million and $56 Million for Q4 and FY 2021, respectivelyMIAMI, March 17, 2022 (GLOBE NEWSWIRE) — Ayr Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“Ayr” or the “Company”), a vertically-integrated cannabis multi-state operator (MSO), is reporting financial results for the three and twelve months ended December 31, 2021. Unless otherwise noted, all results are presented in U.S. dollars. Jonathan Sandelman, Founder, Chairman and CEO of Ayr, said, “2021 was a transformative year for Ayr, with outsized revenue and Adjusted EBITDA growth, and an expanded operating footprint...

Liquidia Corporation Reports Full-Year 2021 Financial Results and Provides Corporate Update

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

– Received tentative FDA approval of YUTREPIA™ (treprostinil) inhalation powder – Expanded use of Treprostinil Injection to include subcutaneous administration – Preparing to launch YUTREPIA in late-2022 pending final FDA approval – Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., March 17, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for full-year ended December 31, 2021. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the 2021 financial results and provide a corporate update. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “Last year, we achieved every goal we set by increasing sales of Treprostinil Injection, securing tentative approval of YUTREPIA,...

CTG to Webcast Presentation at the Sidoti Spring 2022 Virtual Investor Conference

Written by Customer Service on March 17, 2022. Posted in Public Companies.

BUFFALO, N.Y., March 17, 2022 (GLOBE NEWSWIRE) — CTG (Nasdaq: CTG) (“Company”), a leading provider of digital IT solutions and services in North America and Western Europe, today announced that Filip Gydé, President and Chief Executive Officer, and John Laubacker, Chief Financial Officer, will present at the Sidoti Spring 2022 Virtual Investor Conference on Thursday, March 24, 2022 at 10:45 a.m. Eastern Time. A live webcast of the event with accompanying slides will be available on the Investor Relations section of CTG’s website at investors.ctg.com/news-and-insights/events-and-presentations. An archive of the presentation will be available at the same link following the conference. About CTGCTG is a leading provider of digital transformation solutions and services that accelerate clients’ project momentum and achievement of their...

Efecte Plc: Decisions by the Annual General Meeting 2022

Written by Customer Service on March 17, 2022. Posted in Public Companies.

EFECTE PLC — COMPANY ANNOUNCEMENT — 17 March 2022 at 12:45 Efecte Plc: Decisions by the Annual General Meeting 2022 Efecte Plc held its Annual General Meeting on 17 March 2022 at the Company headquarters at the address Säterinkatu 6, Espoo, Finland. The shareholders and their proxy representatives could only participate in the meeting and exercise their shareholder’s rights by voting in advance as well as by submitting counterproposals and asking questions in advance. It was not possible to participate in the meeting in person at the meeting venue. The extraordinary meeting procedures were based on the so-called temporary act (375/2021) which came into force on 8 May 2021. Approximately 46 percent of Efecte’s shares were represented at the Meeting. The Meeting decided to adopt the financial statements and consolidated...

Osisko Enters into Agreement to Acquire a Cash-Flowing Silver Stream on the High-Grade CSA Mine

Written by Customer Service on March 17, 2022. Posted in Public Companies.

Figure 1: Near-Mine Exploration Potential Figure 1: Near-Mine Exploration PotentialMONTRÉAL, March 17, 2022 (GLOBE NEWSWIRE) — Osisko Gold Royalties Ltd (the “Corporation” or “Osisko”) (OR: TSX & NYSE) is pleased to announce that its wholly-owned subsidiary, Osisko Bermuda Limited (“OBL”), has entered into a binding agreement with Metals Acquisition Corp. (“MAC”) (MTAL: NYSE) with respect to a US$90 million silver stream (the “Silver Stream”) to facilitate MAC’s acquisition of the producing CSA mine in New South Wales, Australia (“CSA” or the “Mine”). MAC announced today that it has entered into an agreement to acquire 100% of the shares of the owner of CSA from a subsidiary of Glencore plc (the “Acquisition Transaction”). OBL has also provided MAC with an option to draw up to an additional US$100 million in upfront proceeds...

InvestmentPitch Media Video Discusses Dynacor Gold Mines’ February Gold Sales of US$16.7 Million, or Approximately CDN$21.2 Million, a 40.3% Increase over February 2021

Written by Customer Service on March 17, 2022. Posted in Dividend Reports And Estimates.

VANCOUVER, British Columbia, March 17, 2022 (GLOBE NEWSWIRE) — Montreal-based Dynacor Gold Mines (TSX:DNG), a dividend-paying industrial gold ore processor, has reported its monthly gold sales for February. The company reported February gold sales of US$16.7 million (unaudited), or approximately CDN$21.2 million, a 40.3% increase over February 2021. A Media Snippet accompanying this announcement is available by clicking on the image or link below:For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company. The video is available for viewing on “InvestmentPitch.com” and on “YouTube”. If these links are not enabled, please visit www.InvestmentPitch.com and enter “Dynacor” in the search box. Dynacor also saw a 13.6% month-over-month increase from January....

CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer

Written by Customer Service on March 17, 2022. Posted in Public Companies.

In November 2019, CENTOGENE first announced the signing of a data access and collaboration agreement to discover and validate novel genetic and biochemical targets for the potential development of new therapies for rare diseases New research phase aims to substantiate earlier results and further leverage CENTOGENE’s Bio/Databank to evaluate rare genetic causes of neurodegenerative diseasesROSTOCK, Germany and BERLIN, March 17, 2022 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced an expansion of the Company’s data access and collaboration agreement with Pfizer Inc. The initial agreement, which granted Pfizer access to data of interest from CENTOGENE’s Bio/Databank, was established in 2019 to advance...

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea

Written by Customer Service on March 17, 2022. Posted in Public Companies.

LA JOLLA, Calif., March 17, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Korean Intellectual Property Office which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of advanced nonalcoholic steatohepatitis (NASH). Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035. The allowed claims cover MN-001 (tipelukast) and MN-002 for the treatment of a patient with advanced NASH wherein the treatment is for reducing hepatic fibrosis in a patient suffering from advanced NASH. The allowed claims also cover advanced NASH patients...

WIRELESS TELECOM GROUP ANNOUNCES FOURTH QUARTER AND YEAR-END 2021 FINANCIAL RESULTS

Written by Customer Service on March 17, 2022. Posted in Public Companies.

Highlights for the year ended December 31, 2021:● Net revenues of $49.2 million, an increase of 18.0% compared to the same period last year● Gross Profit of $25.1 million, or 50.9% of net revenue, an increase of $4.1 million or 19.6% compared to the same period last year● Net income of $1.5 million, compared to a net loss of $8.1 million for the same period last year● Non-GAAP Adjusted EBITDA of $3.7 million, compared to Non-GAAP Adjusted EBITDA of $1.8 million for the same period last year● Cash provided by operations of $4.6 million, compared to $3.0 million for the same period last year● Excluding Microlab, backlog at December 31, 2021, was $9.2 million, a $2.1 million, or 30.4% year-over-year increaseHighlights for the quarter ended December 31, 2021:● Signed an agreement for the sale of Microlab to RF Industries...

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome expected in 4Q22 Clinical and regulatory updates from ongoing chronic neutropenia Phase 1b trial anticipated during 2Q/3Q 2022 Additional Waldenström’s macroglobulinemia Phase 1b data expected in second half of 2022; supportive pre-clinical data to be presented at AACR 2022 Conference call today at 8:30 a.m. EDT BOSTON, March 17, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today reported financial results for the fourth quarter and twelve months ended December 31, 2021, and provided a corporate update. “We are very pleased with our many accomplishments in 2021, particularly completing enrollment...

Day: March 17, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice